Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: purified talc; amaranth aluminium lake; titanium dioxide; stearic acid; magnesium stearate; macrogol 6000; indigo carmine aluminium lake; polyvinyl acetate phthalate; calcium silicate; diethyl phthalate; povidone; hypromellose; citric acid monohydrate; hyprolose - epilepsy: primary generaliszed epilepsies (petit mal absences, various forms of myoclonic epilepsies and tonic-clonic grand mal seizures). partial (focal) epilepsies either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: purified talc; magnesium stearate; titanium dioxide; stearic acid; indigo carmine aluminium lake; calcium silicate; polyvinyl acetate phthalate; hypromellose; citric acid monohydrate; diethyl phthalate; hyprolose; amaranth aluminium lake; povidone; macrogol 6000 - epilepsy: primary generalised epilepsies (petit mal absences, various forms of myoclonic epilepsies and tonic-clonic grand mal seizures). partial (focal) epilepsies either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol hemihydrate, quantity: 1.033 mg (equivalent: estradiol, qty 1 mg); drospirenone, quantity: 2 mg - tablet, film coated - excipient ingredients: povidone; hypromellose; magnesium stearate; lactose monohydrate; purified talc; macrogol 6000; titanium dioxide; pregelatinised maize starch; maize starch; iron oxide red - hormone replacement therapy (hrt) for use in the short-term treatment in postmenopausal women with an intact uterus of the climacteric syndrome caused by deficient endogenous oestrogen production due to natural menopause, hypogonadism, castration or primary ovarian failure.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - glibenclamide, quantity: 5 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; pregelatinised maize starch; lactose monohydrate; purified talc; maize starch - daonil and semi-daonil are indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (type 2) whose hyperglycaemia cannot be controlled by diet alone. because of its broad and predictable action, daonil and semi-daonil are often suitable for the management of patients who have failed to respond to other oral antidiabetics.,in initiating treatment for non-insulin-dependent diabetes, diet should be emphasised as the primary form of treatment. caloric restriction and weight loss are essential in the obese diabetic patient. proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycaemia. the importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible. if this treatment programme fails to reduce symptoms and/or blood glucose the use of an oral sulphonylurea should be considered. use of daonil and semi-daonil must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; potato starch; lactose monohydrate; ascorbyl palmitate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, livial should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). livial should only be continued for as long as the benefit outweighs the risks.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; potato starch; ascorbyl palmitate; magnesium stearate; mannitol - - short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women.,- second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: mannitol; lactose monohydrate; magnesium stearate; potato starch; ascorbyl palmitate - - short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women.,- second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 2 mg - tablet, sugar coated - excipient ingredients: magnesium stearate; macrogol 6000; sucrose; glycol montanate; calcium carbonate; povidone; maize starch; lactose monohydrate; purified talc - indications as at 19 july 2004: short term treatment of climacteric complaints after the cessation of monthly bleeding, or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness. progynova has also a favourable influence on bladder irritation (a not infrequent occurrence in the climacteric), signs of cutaneous and mucosal involution (particularly in the genital region) which normally occur with advancing age.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - folic acid, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; povidone; lactose; crospovidone - treatment of megaloblastic anaemia due to a deficiency of folic acid; prophylaxis during pregnancy and lactation.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - folic acid, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose; povidone; magnesium stearate; maize starch; crospovidone - treatment of megaloblastic anaemia due to a deficiency of folic acid; prophylaxis during pregnancy and lactation